DICHLORPHENAMIDE TABLETS
The FDA-approved generic medication to treat primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

HOW TO SAVE ON TORRENT PHARMA’S DICHLORPHENAMIDE TABLETS
This offer only applies to the following NDC Code:
13668-0676-01 Dichlorphenamide Tablets 50MG 100CT
Dichlorphenamide Copay Savings Card
If you have commercial insurance, pay as little as $0 per prescription
Benefits/Cost of the Savings Program
Eligible patients will pay as little as $0, up to a maximum copay assistance of $10,000 per calendar year. If the drug is not covered, eligible patients may receive one (1) month free product one use per lifetime
Eligibility
Copay program offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please see complete Program Terms, Conditions and Eligibility Criteria
INDICATION
Dichlorphenamide tablets are an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants
IMPORTANT SAFETY INFORMATION
Contraindications
Hepatic insufficiency
Severe pulmonary obstruction
Hypersensitivity to dichlorphenamide or other sulfonamides
Concomitant use with high dose aspirin
Warnings and Precautions
Hypersensitivity and Other Life-Threatening Reactions: discontinue dichlorphenamide at the first appearance of skin rash or any sign of immune-mediated or idiosyncratic adverse reaction
Hypokalemia: baseline and periodic measurements of serum potassium are recommended; if hypokalemia develops or persists, consider reducing the dose or discontinuing dichlorphenamide and correcting potassium levels
Metabolic acidosis: baseline and periodic measurements of serum bicarbonate are recommended; if metabolic acidosis develops or persists, consider reducing the dose or discontinuing dichlorphenamide
Falls: consider reducing the dose or discontinuing dichlorphenamide in patients who experience falls
Adverse Reactions
Most common adverse reactions (incidence at least 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state
Drug Interactions
Aspirin: anorexia, tachypnea, lethargy and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. The concomitant use of dichlorphenamide and high-dose aspirin is contraindicated. Dichlorphenamide should be used with caution in patients receiving lower doses of aspirin.
Use in Specific Populations
Pregnancy: Based on animal data, may cause fetal harm
To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma, Inc. at 1-800-912-9561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see Full Prescribing Information